BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6421
- Registration Number
- NCT00496769
- Locations
- 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Kaiser Permanente Medical Center, West Los Angeles, Los Angeles, California, United States
🇺🇸Southwest Heart, Tucson, Arizona, United States
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
- Conditions
- Melanoma
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00495066
- Locations
- 🇧🇷
Instituto ÉTICA - AMO - Assistência Multidisciplinar em Oncologia, Salvador, Bahia, Brazil
🇧🇷Hospital Sao Jose - Beneficencia Portuguesa - Oncology Center, Sao Paulo, SP, Brazil
🇧🇷Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
- Conditions
- Antiplatelet Aggregation
- Interventions
- Procedure: Blood Collection
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 103
- Registration Number
- NCT00493779
- Locations
- 🇬🇧
Local Institution, Southampton, Hampshire, United Kingdom
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 217
- Registration Number
- NCT00484289
- Locations
- 🇯🇵
Local Institution, Chiba-Shi, Japan
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2010-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT00482703
- Locations
- 🇯🇵
Local Institution, Kyoto, Japan
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 260
- Registration Number
- NCT00481325
- Locations
- 🇺🇸
Us Clinical Research Centers, Llc, Costa Mesa, California, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸Pivotal Research Centers, Mesa, Arizona, United States
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 547
- Registration Number
- NCT00481247
- Locations
- 🇺🇸
Molecular Md, Portland, Oregon, United States
🇹🇷Local Institution, Kayseri, Turkey
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00479583
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇫🇷Local Institution, Villejuif, France
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT00461110
- Locations
- 🇺🇸
Thomas Jefferson Univ Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University Of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
- Conditions
- Parkinson's Disease
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT00460954
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada